Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pumecitinib gel - Prime Gene Therapeutics

Next Previous
Drug Profile

Pumecitinib gel - Prime Gene Therapeutics

Alternative Names: PG-011

Latest Information Update: 15 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prime Gene Therapeutics
  • Developer Prime Gene Therapeutics; Simcere Pharmaceutical Group
  • Class Acetonitriles; Amines; Anti-inflammatories; Antiallergics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Radioprotectives; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase II/III Seasonal allergic rhinitis
  • Phase II Prurigo nodularis
  • Phase I Dermatitis; Epidermolysis bullosa; Radiodermatitis; Vitiligo

Most Recent Events

  • 02 Jun 2026 Pumecitinib gel licensed to Simcere Pharmaceutical Group in Mainland China, Hong Kong, and Macau (Simcere Pharmaceutical Group pipeline, July 2026)
  • 02 Jun 2026 Preregistration for Atopic dermatitis (In adults, In adolescents) in China (Topical) (Simcere Pharmaceutical Group pipeline, July 2026)
  • 17 Sep 2025 Chemical structure information added.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top